Clinical trials
Acute Lymphoid Leukemia clinical trials
Below are recruiting acute lymphoid leukemia clinical trials, each written for real people, not researchers. We’re tracking 51 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05327894RecruitingPhase 3
Infants with a specific leukemia genetic change
This study tests a treatment plan for babies under 1 year with leukemia that has a KMT2A gene rearrangement. It may help by trying to improve outcomes in this high-risk group, sometimes using a drug called blinatumomab (depending on eligibility).
Buenos AiresAges 1 day–1 year - NCT03670966RecruitingPhase 1/Phase 2
Targeted iodine therapy, then donor transplant for hard leukemias
This trial tests an antibody-linked radioactive iodine treatment, followed by a donor stem cell transplant, for people with relapsed or refractory high-risk acute leukemia or certain MDS. It may help patients by targeting leukemia cells and then using a new immune system to control the disease.
Seattle, WashingtonAges 18–75 - NCT03630991RecruitingPhase 1
Calcium chelator medicine for AML or MDS during chemotherapy
This Phase 1 study tests whether edetate calcium disodium (also called succimer) can be safely given to people with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) while they are on chemotherapy. The goal is to learn the safest dose and whether it has signs of helping the blood cancer respond to treatment.
Houston, TexasAges 1 year+ - NCT03326921RecruitingPhase 1
T cell treatment for leukemia after a bone marrow transplant
This early-phase trial tests an immune “T cell” therapy made to recognize a specific leukemia target. It is for people whose acute leukemia has come back (relapsed) or did not fully respond after receiving a donor stem cell transplant.
Seattle, WashingtonAges Up to 80 years - NCT03471260RecruitingPhase 1/Phase 2
Ivosidenib and venetoclax for IDH1-mutated leukemia or MDS
This Phase 1/2 study tests whether the medicines ivosidenib and venetoclax (with or without azacitidine) can help people with certain “IDH1-mutated” blood cancers like AML or high-risk MDS. It’s meant for patients whose disease has come back, doesn’t respond, or who can’t safely get standard chemotherapy.
Boston, MassachusettsAges 18 years+ - NCT03263572RecruitingPhase 2
Study medicines for Philadelphia-positive ALL or relapsed leukemia
This Phase 2 trial tests a combination of medicines to treat Philadelphia chromosome–positive (Ph-positive) or BCR-ABL–positive acute lymphoblastic leukemia (ALL), including cases that have come back or did not respond. It may help by targeting specific leukemia signals while also aiming to improve disease control.
Houston, TexasAges 18 years+ - NCT03676504RecruitingPhase 1/Phase 2
CAR T cell therapy for relapsed CD19 blood cancers
This trial tests a type of personalized immune treatment (CD19 CAR T cells made from your T cells) for adults (and children with ALL) whose CD19-positive blood cancer has come back or didn’t respond. It may help your immune system recognize and attack cancer cells that still have CD19.
HeidelbergAges 3 years+ - NCT05031897RecruitingPhase 2
Haplo transplant with reduced donor mismatch and radiation
This trial tests a special bone marrow/stem cell transplant approach using a partially matched family donor, along with conditioning treatment that involves radiation. It aims to help treat certain blood cancers by replacing damaged blood-forming cells with new ones from the donor.
Philadephia, PennsylvaniaAges 18 years+ - NCT05334069Recruiting
Blood test study for early cancer detection in patients
This study collects blood from people with cancer and people without cancer (or with possible cancer) to test whether new blood tests can detect cancer earlier. Your blood samples help researchers evaluate how well these tests work.
Anchorage, AlaskaAges 40–75 - NCT06803745Recruiting
Comparing two radiation doses for leukemia transplant
This trial tests whether a lower or higher dose of total body irradiation works better for people with acute leukemia getting a stem cell transplant for the first time. It aims to find the safest and most effective radiation level to prepare your body for the transplant.
Baltimore, MarylandAges Any age - NCT06481228Recruiting
TKI plus chemo and CAR-T for newly diagnosed Ph+ ALL
This trial tests combining a targeted drug (TKI) with chemotherapy and then CAR-T cells for adults who are newly diagnosed with Philadelphia chromosome-positive ALL. The goal is to see if this combination is safe and effective.
TianjinAges 18 years+ - NCT03104491RecruitingPhase 1/Phase 2
Inotuzumab after transplant for CD22-positive leukemia
This trial studies inotuzumab ozogamicin, a leukemia-targeting medicine, given after an allogeneic stem cell transplant. It’s for people with CD22-positive acute lymphoblastic leukemia (ALL) to help prevent relapse and improve outcomes after transplant.
Westwood, KansasAges 16–75 - NCT06696833RecruitingEarly Phase 1
CD19-targeted CAR-T cell therapy for relapsed B-ALL
This trial tests a new type of immune cell therapy (CAR-γδT cells) that targets CD19 on leukemia cells. It is for people with B-cell acute lymphoblastic leukemia that has not responded to treatment or has come back.
Suzhou, China, JiangsuAges 14 years+ - NCT06308588RecruitingPhase 1/Phase 2
Blinatumomab and asciminib for Ph+ ALL
This trial tests a combination of two targeted drugs (blinatumomab and asciminib) for people with a specific type of leukemia (Ph+ ALL). The goal is to see if the combination works better than either drug alone in controlling the leukemia.
The Bronx, New YorkAges 18 years+ - NCT06529731RecruitingPhase 2
Interferon-Gamma and Donor Cells for Relapsed Leukemia After Transplant
This trial tests combining a protein called interferon-gamma with an infusion of donor white blood cells to treat AML or MDS that returned after a stem cell transplant. The goal is to see if this combination helps the donor cells attack the cancer more effectively.
St Louis, MissouriAges 18 years+ - NCT06173518RecruitingPhase 1
CAR T-cell therapy for children with B-cell leukemia or lymphoma
This trial tests a CAR T-cell therapy that targets CD19 on cancer cells. It is for children whose B-cell acute lymphoblastic leukemia or aggressive B-cell non-Hodgkin lymphoma has come back or not responded to other treatments.
Los Angeles, CaliforniaAges birth–18 years - NCT04307576RecruitingPhase 3
Study for newly diagnosed ALL children and young adults
This Phase 3 trial studies a treatment plan for people up to age 45 who are newly diagnosed with B-cell or T-cell acute lymphoblastic leukemia (ALL). The goal is to see whether the study treatment improves outcomes compared with standard approaches.
BrusselsAges birth–45 years - NCT03911128Recruiting
Treatment protocol for newly diagnosed childhood and young adult ALL
This trial tests a standard treatment plan (a protocol) for people aged 0 to under 46 with newly diagnosed ALL, a cancer of the blood and bone marrow. It may help by making sure patients receive the right therapy based on their specific ALL subtype.
AalborgAges birth–45 years - NCT07284927RecruitingPhase 1
LV009 injection for blood and lymph cancers
This trial tests a new treatment called LV009, a type of CAR-T cell therapy, for people with certain blood cancers (like leukemia or lymphoma) that have CD19 on their cells. The therapy uses your own immune cells to fight the cancer.
Suzhou, JiangsuAges 18–70 - NCT07312630RecruitingEarly Phase 1
A study of LV009 for certain blood cancers
This trial tests an experimental treatment called LV009 for people with certain types of blood cancers that have come back or not responded to previous treatments. The treatment targets a protein called CD19 found on cancer cells.
Hefei, AnhuiAges 18–70 - NCT05865301Recruiting
Outcomes after approved immunotherapy for young blood cancer patients
This study looks at the real-world results of treating certain B-cell blood cancers in children and young adults with commercially available immunotherapy. It may help doctors better understand how these treatments work for patients after relapse or when they need additional therapy.
Tucson, ArizonaAges Up to 26 years - NCT02781883RecruitingPhase 2
Test drug BP1001 with venetoclax and decitabine for AML
This Phase 2 study tests BP1001 added to venetoclax plus decitabine in adults with acute myeloid leukemia (AML). It aims to improve leukemia control in people who may not be able to get standard intensive chemotherapy.
Los Angeles, CaliforniaAges 18 years+ - NCT06686108RecruitingPhase 2
Medication combo to prevent lymphoma relapse after transplant
This trial tests a combination of two drugs (a demethylating agent and venetoclax) to help prevent high-risk T-cell lymphoma or leukemia from coming back after a stem cell transplant. It is for patients who have certain risk factors for relapse.
ShanghaiAges 14–55 - NCT07066397RecruitingPhase 1
CAR-T cell therapy for relapsed B-cell ALL
This trial tests a new CAR-T cell therapy (FIT-CD19-CAR-T) for adults with B-cell acute lymphoblastic leukemia that has come back or not responded to treatment. The goal is to see if this treatment is safe and can help control the leukemia.
TaipeiAges 18 years+
Hear when a new Acute Lymphoid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for acute lymphoid leukemia?
- Yes. Clin2 currently lists 51 recruiting acute lymphoid leukemia studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a acute lymphoid leukemia trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a acute lymphoid leukemia trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.